Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free CDTTW Stock Alerts

Conduit Pharmaceuticals (CDTTW) Competitors

$0.01 +0.00 (+3.39%)
As of 08/13/2026 03:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CDTTW vs. SXTPW, BFRIW, CINGW, CMRAW, and FBIOP

Should you buy Conduit Pharmaceuticals stock or one of its competitors? Conduit Pharmaceuticals's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Comera Life Sciences (CMRAW), and Fortress Biotech (FBIOP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Conduit Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.87 equaled Conduit Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Conduit Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Conduit Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Biofrontera had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 3 mentions for Biofrontera and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.87 beat Biofrontera's score of 0.96 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Positive
Conduit Pharmaceuticals Very Positive

Summary

Biofrontera beats Conduit Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Cingulate had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.87 beat Cingulate's score of 1.44 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Positive
Conduit Pharmaceuticals Very Positive

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Cingulate and Conduit Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Comera Life Sciences?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Comera Life Sciences. Conduit Pharmaceuticals' average media sentiment score of 1.87 beat Comera Life Sciences' score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

Conduit Pharmaceuticals beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIOP) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
Fortress BiotechN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$66.16MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Fortress Biotech had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.87 beat Fortress Biotech's score of 0.30 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Fortress Biotech Neutral
Conduit Pharmaceuticals Very Positive

Summary

Fortress Biotech beats Conduit Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

Get Conduit Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTTW vs. The Competition

Export
MetricConduit PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.88B$7.07B$12.99B
Dividend YieldN/A2.70%2.58%10.72%
P/E RatioN/A783.89269.6325.21
Price / SalesN/A746.84596.2799.03
Price / CashN/A67.4570.5350.75
Price / BookN/A10.6313.136.24
Net IncomeN/A$2.77B$3.45B$347.70M
7 Day PerformanceN/A-0.08%0.78%0.87%
1 Month PerformanceN/A0.09%1.45%0.90%
1 Year PerformanceN/A161.21%67.09%20.13%

Conduit Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDTTW
Conduit Pharmaceuticals
N/A$0.01
+3.4%		N/A-35.1%$0.00N/AN/A7
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-67.6%$0.00$1.00MN/A2
BFRIW
Biofrontera
N/A$0.03
+4.9%		N/A-81.6%$0.00$43.20MN/A70
CINGW
Cingulate
N/A$0.01
-32.1%		N/A-87.9%$0.00N/AN/A20
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CDTTW) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel